Ryne Bio
Howard Federoff, MD PhD, is Chief Medical Officer and Scientific co-Founder at Ryne Bio. Recently as CEO of Aspen Neuroscience, he led the company through a $70MM Series A financing to advance an iPSC program targeting Parkinson's Disease. Subsequently, as President & CEO of Brooklyn ImmunoTherapeutics, he executed a pivot into iPSC immuno-oncology. Dr. Federoff is a recognized thought leader and serial entrepreneur in the field of advanced medicines for diseases of the nervous system, focused on the development of gene and cellular therapy strategies to interdict pathogenesis. As a clinician scientist he has previously served roles as dean of medicine, vice chancellor for health affairs, executive vice president for health sciences and health system CEO, as President of the American Society for Experimental Therapeutics, American Society for Neural Transplant and Repair, and as vice President of the National Academy of Inventors. Dr. Federoff has published more than 300 manuscripts, review articles, chapters and US Patents.
This person is not in any teams
This person is not in any offices
Ryne Bio
Ryne Bio is a biotechnology company advancing off-the-shelf neuron replacement therapies as potent disease-modifying treatments for neurological disorders. To achieve this they leverage induced pluripotent stem cell (iPSC) technology, which enables precision manufacture of therapeutically relevant human neurons. Their lead program targeting Parkinson’s Disease is a cryopreserved iPSC dopamine neuron progenitor (RNDP-001) that can be reliably manufactured and delivered